Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy right now. ATAI Life Sciences holds a Strong Buy consensus from 8 analysts, with a 12‑month average target of $12.71 (range $10–$16), implying a 204% upside from the current $4.18.

Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation

Pressmaster/Shutterstock.com

On December 11, the United States Patent and Trademark Office granted Atai Life Sciences N.V. a new patent for EMP-01, an oral formulation for the treatment of social anxiety disorder. The patent covers the drug substance of EMP-01 and will provide exclusivity through 2043.

The patent identifies a highly crystalline thermodynamically stable HCl salt form of (R)-MDMA with high aqueous solubility and low hygroscopicity. The patent is poised to support the company’s strategy to develop innovative, differentiated therapies for addressing significant mental health needs.

EMP-01 is currently in clinical development for social anxiety disorder, with exploratory Phase 2a underway. The company is on course to deliver topline data in the first quarter of next year, as the drug has already demonstrated a unique dose-dependent effect profile in Phase 1 trials.

“EMP-01 is an important asset in our pipeline, and securing this patent issuance in the U.S. further strengthens our ability to advance the program while delivering meaningful value for patients and shareholders. We look forward to reporting topline data from the exploratory Phase 2a study evaluating EMP-01 in adults with social anxiety disorder in the first quarter of 2026,” said Chief Executive Officer and Co-founder of AtaiBeckley.

Atai Life Sciences N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on creating novel mental health treatments, primarily using psychedelic-based therapies like DMT (VLS-01) and R-MDMA (EMP-01) for conditions like treatment-resistant depression (TRD) and social anxiety, aiming for rapid, effective, and scalable solutions to address gaps in current mental healthcare.

While we acknowledge the potential of ATAI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATAI and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire David Tepper’s Top 12 Stock Picks Heading into 2026 and 12 Best Industrial Stocks to Buy According to Wall Street Analysts.

Disclosure: None. This article is originally published at Insider Monkey.